Gez E, Sulkes A, Yablonsky-Peretz T, Weshler Z
J Surg Oncol. 1986 Feb;31(2):139-42. doi: 10.1002/jso.2930310213.
Twenty-five patients with locally advanced but resectable adenocarcinoma of the stomach were given concomitant postoperative radiotherapy to the tumor bed and chemotherapy with 5-Fluorouracil (5-FU). Twenty-two of the patients had regional lymph node involvement and seven had residual tumor in the surgical margins. Radiotherapy was delivered to a total dose of 5,000 rads in 7 weeks with a two-week split. 5-FU was given daily the first 3 days of each treatment period and was then continued weekly for a minimum of 1 year. At a median follow-up time of 19 months, 11 patients have relapsed, two locally and nine distally, and all have died. Thirteen patients remain alive, all but one disease-free, for a median of 21 months from diagnosis. One additional patient died of unrelated causes, free of tumor. The actuarial median survival for the whole group stands at 33 months with a projected 5-year survival of 40%. Treatment has been well tolerated.
25例局部晚期但可切除的胃腺癌患者在术后接受了肿瘤床同步放疗以及5-氟尿嘧啶(5-FU)化疗。其中22例患者有区域淋巴结受累,7例手术切缘有残留肿瘤。放疗在7周内分两周分割给予,总剂量为5000拉德。5-FU在每个治疗周期的前3天每日给药,然后每周持续给药至少1年。在中位随访时间19个月时,11例患者复发,2例为局部复发,9例为远处复发,且均已死亡。13例患者仍存活,除1例有疾病外,其余均无病生存,自诊断起中位时间为21个月。另有1例患者死于无关原因,无肿瘤。全组患者的精算中位生存期为33个月,预计5年生存率为40%。治疗耐受性良好。